Cytokinetics Q3 2024 Update: Notes, Loans, and R&D

TL;DR

**Cytokinetics Q3: R&D hums, debt looms. Notes due '26 & '27, Royalty Pharma loans in play.**

AI Summary

Cytokinetics Inc. reported its third quarter 2024 results, ending September 30, 2024. The company's financial filings indicate ongoing research and development activities, including those related to the Corxel Aficamten License and Collaboration Agreement. Key financial instruments mentioned include Convertible Senior Notes due 2027 and 2026, as well as various loan tranches from Royalty Pharma.

Why It Matters

This filing provides insight into Cytokinetics' financial health and ongoing development of its pharmaceutical products, which could impact future drug availability and company valuation.

Risk Assessment

Risk Level: medium — The company's financial structure involves significant debt instruments like convertible senior notes and royalty-backed loans, which carry inherent financial risks.

Key Numbers

• 2024-09-30 — Reporting Period End Date (Third quarter financial results)
• 2024-11-07 — Filing Date (Date the 10-Q was submitted)

Key Players & Entities

• CYTOKINETICS INC (company) — Filer
• Corxel Aficamten License and Collaboration Agreement (agreement) — Research and Development Activity
• Convertible Senior Notes Due 2027 (debt) — Financial Instrument
• Convertible Senior Notes Due 2026 (debt) — Financial Instrument
• Royalty Pharma (company) — Lender

FAQ

Key Financial Figures

• $0.001 — : Title of each class Common Stock, $0.001 par value Trading symbol CYTK Nam

Filing Documents

• cytk-20240930.htm (10-Q) — 2592KB
• cytk-ex10_1.htm (EX-10.1) — 34KB
• cytk-ex10_2.htm (EX-10.2) — 38KB
• cytk-ex31_1.htm (EX-31.1) — 15KB
• cytk-ex31_2.htm (EX-31.2) — 15KB
• cytk-ex32_1.htm (EX-32.1) — 9KB
• img196648343_0.jpg (GRAPHIC) — 2KB
• 0000950170-24-123283.txt ( ) — 9605KB
• cytk-20240930.xsd (EX-101.SCH) — 1481KB
• cytk-20240930_htm.xml (XML) — 1447KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 7

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 7 Condensed Consolidated Balance Sheets 7 Condensed Consolidated Statements of Operations and Comprehensive Loss 8 Condensed Consolidated Statements of Stockholders' (Deficit) Equity 9 Condensed Consolidated Statements of Cash Flows 11 Notes to Condensed Consolidated Financial Statements 12

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 27

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 45

Controls and Procedures

Item 4. Controls and Procedures 46

OTHER INFORMATION

PART II. OTHER INFORMATION 47

Legal Proceedings

Item 1. Legal Proceedings 47

Risk Factors

Item 1A. Risk Factors 47

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 76

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 76

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 76

Other Information

Item 5. Other Information 76

Exhibits

Item 6. Exhibits 77

SIGNATURES

SIGNATURES 79 2 Table of Contents Glossary of Terms Unless the context requires otherwise, references to "Cytokinetics," "the Company," "we," "us" or "our" in this Quarterly Report on Form 10-Q refer to Cytokinetics, Incorporated and its subsidiaries. References to "Notes" in this Form 10-Q are to the Notes to the Condensed Consolidated Financial Statements in this Form 10-Q. We also have used other specific terms in this Form 10-Q, most of which are explained or defined below: Term/Abbreviation Definition 2004 Plan Cytokinetics' Amended and Restated 2004 Equity Incentive Plan 2020 RTW Transactions The transactions contemplated by the RTW Royalty Purchase Agreement, Corxel Aficamten License Agreement and the Common Stock Purchase Agreements, dated July 14, 2020, by and between Cytokinetics and the RTW Investors 2021 RTW Transactions The transactions contemplated by the Corxel OM License Agreement and the Common Stock Purchase Agreements, dated December 20, 2021 by and between Cytokinetics and the RTW Investors 2022 RPI Transactions The transactions contemplated by the RP Multi Tranche Loan Agreement and the RP Aficamten RPA 2024 RPI Transactions The transactions contemplated by the 2024 RP OM Loan Agreement, the RP CK-586 RPA, the RP Stock Purchase Agreement, the 2022 RP Multi Tranche Loan Agreement Amendment and the RP Aficamten RPA Amendment 2026 Notes Cytokinetics' 4% convertible senior notes due 2026 2027 Indenture Indenture Agreement, dated July 6, 2022, between Cytokinetics and U.S. Bank Trust Company, as trustee 2027 Notes Cytokinetics' 3.50% convertible senior notes due 2027 ACA Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act ACACIA-HCM Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM ACC American College of Cardiology AHA American Heart Association ALS amyotrophic lateral sclerosis (als

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

FINANCI AL STATEMENTS

ITEM 1. FINANCI AL STATEMENTS CYTOKINETICS, INCORPORATED CONDENSED CONSOLIDAT ED BALANCE SHEETS (In thousands) (Unaudited) September 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 46,888 $ 113,024 Short-term investments 964,804 501,800 Accounts receivable 244 1,283 Prepaid expenses and other current assets 6,665 11,944 Total current assets 1,018,601 628,051 Long-term investments 269,168 40,534 Property and equipment, net 64,222 68,748 Operating lease right-of-use assets 76,344 78,987 Other assets 7,725 7,996 Total assets $ 1,436,060 $ 824,316 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable $ 11,581 $ 21,507 Accrued liabilities 49,826 42,641 Short-term operating lease liabilities 18,856 17,891 Current portion of long-term debt 11,520 10,080 Derivative liabilities measured at fair value 12,500 — Other current liabilities 5,529 10,559 Total current liabilities 109,812 102,678 Term loans, net 93,017 58,384 Convertible notes, net 551,481 548,989 Liabilities related to revenue participation right purchase agreements, net 448,509 379,975 Long-term operating lease liabilities 114,752 120,427 Liabilities related to RPI Transactions measured at fair value 132,400 — Other non-current liabilities — 186 Total liabilities 1,449,971 1,210,639 Commitments and contingencies Stockholders' deficit Preferred stock — — Common stock 118 102 Additional paid-in capital 2,532,328 1,725,823 Accumulated other comprehensive income (loss) 5,387 ( 10 ) Accumulated deficit ( 2,551,744 ) ( 2,112,238 ) Total stockholders' deficit ( 13,911 ) ( 386,323 ) Total liabilities and stockholders' deficit $ 1,436,060 $ 824,316 The accompanying notes are an integral part of these condensed consolidated financial stateme

View Full Filing

View this 10-Q filing on SEC EDGAR